Adherium Limited (ASX:ADR): How Smart Inhaler Data Supports Respiratory Monitoring

Aditi Sarkar

14 October 2026 08:14 PM AEDT

Adherium Limited (ASX:ADR): How Smart Inhaler Data Supports Respiratory Monitoring

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Hailie sensors record inhaler use and provide data to patients and healthcare professionals.
The platform combines connected sensors, an app, cloud data services and a clinician portal.
2026 research presentations addressed patient monitoring and healthcare utilisation.
A leadership transition and funding announcements formed part of the company’s 2026 updates.
Data quality, adoption, operating expenditure and financing remain relevant business considerations.

Adherium Limited (ASX:ADR) develops connected respiratory monitoring technology for people managing asthma and chronic obstructive pulmonary disease (COPD). Its Hailie Smartinhaler platform links inhaler-mounted sensors with software that records medication use and shares information with patients and healthcare teams. During 2026, Adherium (ASX:ADR) highlighted real-world respiratory monitoring evidence while continuing to develop its remote patient monitoring activities.

How Hailie Records Inhaler Use

Hailie sensors attach to compatible prescribed inhalers and transmit information using Bluetooth-enabled technology. The connected app records medication activation, timing and adherence, while a clinician portal makes information available for review. The system is designed to support a clearer account of whether prescribed inhalers are being used as directed, rather than relying only on patients’ recollection.

Adherium (ASX:ADR) also describes physiological monitoring features in its next-generation sensors. These include inhalation flow information and measures relating to inhaler technique. Such data are distinct from a simple record of a device being activated: they can help clinicians assess how a patient used an inhaler, although sensor readings do not independently establish whether a particular treatment achieved its intended clinical result.

What the 2026 Research Presentations Reported

In May 2026, Adherium (ASX:ADR) reported that two independent studies featuring Hailie-generated data were presented at a respiratory medicine conference. One involved the iCARE remote-monitoring programme, which combined connected inhalers with other monitoring devices, patient engagement tools and clinical oversight.

The company’s summary of the iCARE findings reported a 57% reduction in total cost of care per patient, 50% fewer hospital admissions, 20% fewer emergency department visits and 92% patient retention at 12 months. These were programme-level findings, not proof that the inhaler sensors alone caused the changes. A separate study reported differences between self-reported medication adherence and objectively recorded usage.

Commercial Model and 2026 Corporate Developments

Adherium (ASX:ADR) markets its platform to respiratory-care organisations and providers using remote patient monitoring. The commercial proposition combines connected devices with ongoing data services. The extent to which this activity translates into recurring revenue depends on deployment volumes, continued use, service agreements and associated costs.

In July 2026, Adherium announced that its chief executive officer had stepped down and that its chief commercial officer had been appointed interim chief executive. The company subsequently reported financing developments, including consolidation of funding into an A$4.67 million term loan in September 2026 and an AUD$700,000 short-term loan facility announced in October. The existence of financing arrangements does not by itself establish future cash adequacy or profitability.

Operational Constraints and Data Interpretation

The effectiveness of a monitoring service depends on sensor compatibility, reliable data capture and engagement by patients and healthcare professionals. Clinical adoption, implementation expenses and regulatory requirements can affect delivery. For Adherium (ASX:ADR), financing terms and cash usage are also material when assessing its capacity to support commercial operations.

Key Insights

Adherium’s Hailie technology combines objective inhaler-use records with a clinician-facing monitoring system. Its 2026 presentations supplied findings from programmes using connected respiratory tools, while company announcements documented leadership and funding changes. The distinction between measured adherence, broader care outcomes and company financial performance remains central to understanding the business.

FAQs

Q: What does Adherium Limited do?

A:It develops connected devices and software for monitoring inhaler use in asthma and COPD care.

Q: What is the Hailie Smartinhaler platform?

A:It links inhaler-mounted sensors with a patient app and clinical data services.

Q: Can Hailie capture inhalation technique information?

A:Selected sensors capture physiological measurements, including inhalation flow-related data.

Q: What did the 2026 iCARE findings cover?

A:The reported outcomes covered care costs, hospital use, emergency visits and patient retention within the programme.

Q: Why is monitoring data different from clinical outcomes?

A:Recorded inhaler use describes behaviour; health outcomes also depend on treatment, patient factors and clinical care.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.